These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10426875)

  • 1. Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction.
    Colombo A; Briguori C
    Am Heart J; 1999 Aug; 138(2 Pt 2):S153-7. PubMed ID: 10426875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction.
    Santoro GM; Bolognese L
    Am Heart J; 2001 Feb; 141(2 Suppl):S26-35. PubMed ID: 11174356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction.
    Ferrario M; Repetto A; Lucreziotti S; Ardissino D
    Am Heart J; 1999 Aug; 138(2 Pt 2):S121-5. PubMed ID: 10426870
    [No Abstract]   [Full Text] [Related]  

  • 4. IIb/IIIa receptor blockade in acute myocardial infarction.
    Ferguson JJ; Taqi K
    Am Heart J; 1999 Aug; 138(2 Pt 2):S164-70. PubMed ID: 10426877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do new devices add to the results of PTCA in acute myocardial infarction?
    Moses J; Moussa I
    Am Heart J; 1999 Aug; 138(2 Pt 2):S158-63. PubMed ID: 10426876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in antithrombotic therapy of acute myocardial infarction.
    Gensini GF; Comeglio M; Falai M
    Am Heart J; 1999 Aug; 138(2 Pt 2):S171-6. PubMed ID: 10426878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
    Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
    J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.
    De Luca G; Gibson MC; Hof AW; Cutlip D; Zeymer U; Noc M; Maioli M; Zorman S; Gabriel MH; Secco GG; Emre A; Dudek D; Rakowski T; Gyongyosi M; Huber K; Bellandi F;
    J Cardiovasc Med (Hagerstown); 2013 Nov; 14(11):815-20. PubMed ID: 23519096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
    Shin EK; Son JW; Sohn MS; Jin DK; Park GS; Koh KK; Ahn TH; Choi IS
    Catheter Cardiovasc Interv; 2001 Mar; 52(3):306-12. PubMed ID: 11246241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
    Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
    Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.
    Kaul U; Gupta RK; Haridas KK; Ramesh SS; Sethi KK; Singh B; Agarwal R; Yadave RD; Ghose T; Sapra RR; Bajaj R; Shahi M; Bhagwat A; Kumar P; Mathews OP; Soni PK;
    Catheter Cardiovasc Interv; 2002 Dec; 57(4):497-503. PubMed ID: 12455085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
    Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
    J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
    Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
    J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.